Leases

3 Months Ended

Mar. 31, 2019

10.

Leases

In April 2014, the Company entered into a five-year lease agreement for administrative office space located in Bellaire, Texas. The term of the lease began on August 1, 2014 and terminates on July 31, 2019.

In April 2016, the Company entered into a three-year lease agreement for lab space located in Bellaire, Texas. The term of lease began on May 1, 2016 and terminates on April 30, 2019 and requires Bio-Path to pay $2,500 per month over the term of the lease. In December 2018, we entered into an amendment to the agreement with the term of the extension beginning on May 1, 2019 and terminating on April 30, 2022 and will require Bio-Path to pay $2,575 per month over the term.

At the inception of an agreement, the Company determines if the agreement is a lease based on the unique facts and circumstances in each agreement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For agreements that contain a lease, we identify lease and non-lease components, determine the consideration in the contract, determine whether the lease is an operating or financing lease and recognize ROU assets and lease liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable so we use an incremental borrowing rate based on the information available at the lease commencement date, which represents an estimated rate that would be incurred to borrow over a similar term in a similar economic environment. The incremental borrowing rate utilized on our lease liabilities as of March 31, 2019 was 8.0%.

Our current leases include options to renew which can impact the lease term. The exercise of these options is at the Company’s discretion and we do not include any of these options within the expected lease term as we are not reasonably certain we will exercise these options. Fixed lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis within our consolidated financial statements. Our leases are included in

ROU

assets, current portion of lease liabilities and noncurrent lease liabilities in our consolidated balance sheet as of March 31, 2019.

The following table summarizes our operating lease assets and liabilities as of March 31, 2019:

	ROU Assets and Liabilities
	(in thousands)
Assets:
Operating lease assets	$	113

Liabilities:
Current portion of lease liabilities		54
Noncurrent lease liabilities		59
Total operating lease liabilities	$	113

The following table summarizes our lease related costs as of March 31, 2019:

	Lease Costs
	(in thousands)
Operating lease costs	$	28
Variable lease costs		3
Total lease costs	$	31

The Company made cash payments for its operating leases of $29,000 for the three months ended March 31, 2019. Additionally, the Company had $113,000 in non-cash investing and financing activities for the period ended March 31, 2019 related to addition of ROU assets and corresponding operating lease liabilities recorded as part of the adoption of the new lease standard on January 1, 2019.

The following table summarizes our expected minimum lease payments as of March 31, 2019:

As of March 31, 2019
(in thousands)
2019		52
2020		31
2021		31
2022		10
2023		-
2024 and thereafter		-
Future minimum lease payments		124
Less: Interest		(11	)
Present value of operating lease liabilities	$	113

As of March 31, 2019, the weighted average remaining lease term was 2.4 years.

ASC 840 Disclosures

The following table summarizes our expected minimum lease payments as of December 31, 2018:

As of December 31, 2018
(in thousands)
2019		82
2020		31
2021		31
2022		10
2023		-
2024 and thereafter		-
Future minimum lease payments	$	154

The Company recognized $32,000 in rent expense for office and lab space.